Press Releases<< Back
CHF Solutions Expands Commercial Focus of Fluid Overloaded Patients into the Post-Cardiovascular Surgery Market
Surgical patients are often challenged by fluid overload post procedure due to the extra administration of fluids required during surgery. Excess fluids, if not removed effectively, can pose a potential higher risk for morbidity, mortality, and readmissions.1,2,3,4 Given the synergies between heart failure cardiologists and cardiovascular surgeons in the treatment of heart failure patients suffering from fluid overload, the company believes expanding into the post CV surgical market is a natural next step in commercial expansion.
“The expansion of our sales and marketing team at
About CHF Solutions
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the potential of our expansion into the post-cardiovascular surgery market to be commercially successful and result in growth of the market for Aquadex Flex Flow and the ability of our expanded sales and marketing team to successfully implement the expansion to our commercial strategy. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with, and benefits from, acquired businesses, and other risks and uncertainties described in our filings with the
(1) Iribarne A, Chang H, Alexander JH, et al. Ann Thorac Surg. 2014 Oct; 98(4): 1274-80; (2) Holte K, Sharrock NE, Kehlet H, et al. Br J of Anaesth. 2002 Oct; 89 (4) 622-32; (3) Childs D, Cao Z, Seiberlich LE, et al. Clinicoecon Outcomes Res. 2014 Dec 15; 7:1-8; (4) Morin JF, Mistry B, Langlois Y, et al.
Chief Financial Officer
Source: CHF Solutions, Inc.